Uppsala, Sweden, 27th July 2010 – GE Healthcare, a unit of General Electric Company (NYSE: GE), announces the launch of Biacore™ T200, designed to deliver exceptional sensitivity in the measurement of high quality kinetic, affinity, concentration, specificity, and thermodynamic interaction data, in real time. The system builds upon the success of the widely adopted Biacore T100.
The performance, versatility and sensitivity of Biacore T200 enables analysis of interactions involving the smallest, low molecular weight compounds, interactions of rare targets, and facilitates the analysis of interactions involving G protein-coupled receptors. The outstanding sensitivity of the system also allows antigen immobilization levels so low that interactions with antibody in solution can be analysed, without avidity effects, thus adding flexibility to assay design. In addition, the system expands the range of kinetic parameters that can be studied with the highest precision and confidence, from the fastest on-rates to the slowest off-rates.
Guided workflows and the ability to analyse up to 384 samples in unattended runs facilitates rapid data acquisition for a large range of biomolecular interaction studies, including defining potential drug targets and diagnostic markers, and time- and cost-efficient concentration analysis in vaccine development. Calibration-free concentration analysis enables highly reproducible, precise measurement of active protein concentration, whether or not a standard is available.
Dr. Johan Weigelt, SGC, Karolinska Institutet, commented: “The high sensitivity and information-rich data of Biacore T200 allowed us to assess inhibitor selectivity and identify weak binders not possible with our alternative technology. The findings are of great value as a starting point for development of selective inhibitors of novel PARP enzymes.”
Biacore T200 software also provides dedicated support for confident immunogenicity testing, for detection and characterization of anti-drug antibodies during preclinical and clinical development. The optional GxP Package enables Biacore T200 to integrate seamlessly into GxP-regulated workflows.
For more information please visit: www.gelifescience.com/interactions
For details of DiPIA 2010, (Developments in Protein Interaction Analysis), a leading forum for discussion of the latest developments and trends in the field of biomolecular interaction and stability analysis, please visit: www.gelifesciences.com/dipia2010
About GE Healthcare: GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.
Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
For a high resolution image, please contact College Hill
Contact College Hill Lynne Trowbridge, Katie Odgaard T: +44 (0)20 7866 7858 E : ge-proteins@collegehill.com
Company Name: College Hill Ltd, Company Number: 1036926 Registered Address: The Registry, Royal Mint Court, London EC3N 4QN UK
